Transition From Basal/Bolus to Once-weekly Subcutaneous Semaglutide and Basal Insulin in Patients With T2D

Summary

This study is designed to determine whether therapy with once-weekly sc semaglutide in combination with once-daily insulin degludec will be capable of maintaining (or improving) glycemic control, when substituted for multiple daily injections of insulin (MDI), in patients with T2D with adequate glycemic control (≤ 7.5%) on MDI-based regimens (≤ 80 units of insulin per day), vs. further titration of insulin therapy in those continuing MDI. Weight loss, hypoglycemic episodes, and improvement in diabetes-treatment satisfaction will also be assessed between the two groups.

Timeline

Start

2021-01-18

Primary completion

2023-03-31

Completion

2023-11-01

Publications

• Results Rodriguez P, Breslaw N, Xiao H, Bena J, Jenkins K, Isaacs D, Zhou K, Griebeler ML, Burguera B, Pantalone KM; TRANSITION-T2D Investigators. De-intensification of basal-bolus therapy by replacing prandial insulin with once-weekly subcutaneous semaglutide in individuals with well-controlled type 2 diabetes: A single-centre, open-label randomised trial (TRANSITION-T2D). Diabetes Obes Metab. 2025 Feb;27(2):642-651. doi: 10.1111/dom.16057. Epub 2024 Nov 12.

Drugs

Indications